Stock ERYP PHAXIAM THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights PHAXIAM Therapeutics S.A. Nasdaq

Equities

ERYP

US29604W2070

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phaxiam initiates trial in infective endocarditis
CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus
CI
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq
MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...
Our Logo
Phaxiam to delist ADS from Nasdaq in March
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. ERYP Stock
  5. News PHAXIAM Therapeutics S.A.
  6. Highlights